rs12210271 - PREP

Magnitude 2.2 · 1 study on file

Reported associations

• Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci. - European heart journal (2022) · Ghouse J, Tragante V, Muhammad A, Ahlberg G, Skov MW, Roden DM, Jonsdottir I, Andreasen L, Lundegaard PR, Trudsø LC, Banasik K, Brunak S, Ostrowski SR, Torp-Pedersen C, Pedersen OV, Sørensen E, Køber L, Iversen K, Thorsteinsdottir U, Thorgeirsson G, Ullum H, Gudbjartsson DF, Mosley JD, Holm H, Stefansson K, Bundgaard H, Olesen MS · PubMed 35751511

  To search for sequence variants associated with ACEi discontinuation and to test their association with ACEi-associated adverse drug reactions (ADRs). A genome-wide association study (GWAS) on ACEi discontinuation was conducted, including 33 959 ACEi-discontinuers and 44 041 controls. Cases were defined as persons who switched from an ACEi treatment to an angiotensin receptor blocker. Controls were defined as persons who continued ACEi treatment for at least 1 year. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were computed for ACEi discontinuation risk by mixed model regression analysis. Summary statistics from the individual cohorts were meta-analyzed with a fixed-effects model. To test for association with specific ACEi-associated ADRs, any genome-wide significant (P < 5 ×

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.